One-Shot gene therapy could change wet AMD treatment
Disease control
Recruiting now
This study tests a new gene therapy called LX102 for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The treatment is given as a single injection under the retina and is compared to standard eye injections. The goal is to see if LX102 can i…
Phase: PHASE3 • Sponsor: Innostellar Biotherapeutics Co.,Ltd • Aim: Disease control
Last updated May 17, 2026 07:35 UTC